Original Dataset — Female / Emergency / Diabetes (all medications, first 25 shown)
| Name | Age | Blood Type | Medication | Billing Amount | Date Admitted | Date Discharged | Test Results |
|---|
Three Charts — Treatment Patterns, Outcomes, Cost
Chart 01 — Distribution
Medication
Distribution
Across 74 female emergency diabetes patients, the five medications in the dataset are distributed relatively evenly — but not identically. Aspirin leads with 17 prescriptions, Penicillin follows at 16, Lipitor at 15, Paracetamol at 14, and Ibuprofen at 12.
This near-even spread suggests the prescribing isn't strongly condition-driven for this cohort — if Lipitor were the clinical default for diabetic emergency patients, we'd expect it to dominate. The distribution instead implies physician discretion or protocol variation across hospitals.
Key Takeaway
No single medication dominates this cohort. The spread is flat enough to make outcome comparisons across medications meaningful — none is dramatically over- or under-represented.
Chart 02 — Outcomes
Test Results
by Medication
This is where the data gets interesting. Aspirin patients returned Normal results at the highest rate — 8 out of 17, nearly 47%. Ibuprofen patients were most likely to be Inconclusive (6 of 12, 50%). Lipitor and Penicillin patients showed the highest rate of Abnormal results — 7 and 8 respectively.
It's worth noting this dataset cannot establish causation — sicker patients may be prescribed Penicillin or Lipitor precisely because of more severe presentations. But the pattern is consistent enough to warrant clinical scrutiny.
Key Takeaway
Aspirin: 47% Normal. Penicillin: only 25% Normal with 50% Abnormal. That's a 2× gap in favorable outcomes between the best- and worst-performing medications in this group.
Chart 03 — Cost
Average Billing
by Medication
Paracetamol averages the highest bill at $27,580, followed closely by Lipitor at $26,364. The three other medications cluster between $22,300–$22,500 — a $5,000+ gap separates the expensive tier from the affordable one.
Cross-referencing with Chart 2: Paracetamol's high cost doesn't correspond to better outcomes (only 4 Normal results out of 14). Aspirin achieves the best outcome rate at the second-lowest average cost — making a compelling case for its clinical value in this specific patient profile.
Key Takeaway
Higher billing does not predict better outcomes here. Paracetamol costs ~$5K more per patient than Aspirin, yet produces fewer Normal results. Cost and efficacy are misaligned.
The Argument: Aspirin Outperforms
Taken together, these three charts build a coherent case. The medication distribution is flat enough that no single drug is being selectively prescribed to only mild or only severe cases — the groups are comparable. Yet Aspirin consistently produces the best test outcomes (47% Normal) at one of the lower average billing amounts ($22,503).
Meanwhile, Lipitor and Penicillin — both more expensive or equally priced — produce the worst outcome profiles, with Abnormal results accounting for 47% and 50% of their patients respectively. For this cohort — female, emergency-admitted, diabetic — the data suggests Aspirin is the highest-value medication choice on both clinical and financial dimensions. Further research controlling for admission severity would be needed to make a causal claim, but the correlation is striking.